When should factorial designs be used for late-phase randomised controlled trials?

被引:0
|
作者
White, Ian R. [1 ,2 ]
Szubert, Alexander J. [1 ]
Choodari-Oskooei, Babak [1 ]
Walker, A. Sarah [1 ]
Parmar, Mahesh K. B. [1 ]
机构
[1] UCL, MRC Clin Trials Unit, London, England
[2] UCL, MRC Clin Trials Unit, 2nd Floor, 90 High Holborn, London WC1V 6LJ, England
关键词
Randomised controlled trial; clinical trial; design; factorial; CLINICAL-TRIALS; CHALLENGES; MULTIARM; THERAPY;
D O I
10.1177/17407745231206261
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: A 2 x 2 factorial design evaluates two interventions (A versus control and B versus control) by randomising to control, A-only, B-only or both A and B together. Extended factorial designs are also possible (e.g. 3 x 3 or 2 x 2 x 2). Factorial designs often require fewer resources and participants than alternative randomised controlled trials, but they are not widely used. We identified several issues that investigators considering this design need to address, before they use it in a late-phase setting. Methods: We surveyed journal articles published in 2000-2022 relating to designing factorial randomised controlled trials. We identified issues to consider based on these and our personal experiences. Results: We identified clinical, practical, statistical and external issues that make factorial randomised controlled trials more desirable. Clinical issues are (1) interventions can be easily co-administered; (2) risk of safety issues from co-administration above individual risks of the separate interventions is low; (3) safety or efficacy data are wanted on the combination intervention; (4) potential for interaction (e.g. effect of A differing when B administered) is low; (5) it is important to compare interventions with other interventions balanced, rather than allowing randomised interventions to affect the choice of other interventions; (6) eligibility criteria for different interventions are similar. Practical issues are (7) recruitment is not harmed by testing many interventions; (8) each intervention and associated toxicities is unlikely to reduce either adherence to the other intervention or overall follow-up; (9) blinding is easy to implement or not required. Statistical issues are (10) a suitable scale of analysis can be identified; (11) adjustment for multiplicity is not required; (12) early stopping for efficacy or lack of benefit can be done effectively. External issues are (13) adequate funding is available and (14) the trial is not intended for licensing purposes. An overarching issue (15) is that factorial design should give a lower sample size requirement than alternative designs. Across designs with varying non-adherence, retention, intervention effects and interaction effects, 2 x 2 factorial designs require lower sample size than a three-arm alternative when one intervention effect is reduced by no more than 24%-48% in the presence of the other intervention compared with in the absence of the other intervention. Conclusions: Factorial designs are not widely used and should be considered more often using our issues to consider. Low potential for at most small to modest interaction is key, for example, where the interventions have different mechanisms of action or target different aspects of the disease being studied.
引用
收藏
页码:162 / 170
页数:9
相关论文
共 50 条
  • [31] Randomised controlled trials do not always give the results we want but that doesn’t mean we should abandon randomised controlled trials
    L A Harvey
    Spinal Cord, 2015, 53 : 251 - 251
  • [32] Adenovirus Late-Phase Infection Is Controlled by a Novel L4 Promoter
    Morris, Susan J.
    Scott, Gillian E.
    Leppard, Keith N.
    JOURNAL OF VIROLOGY, 2010, 84 (14) : 7096 - 7104
  • [33] MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary
    Hutchinson, Michael
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (03) : 284 - 285
  • [34] Randomized controlled trials and neuro-oncology: should alternative designs be considered?
    Mansouri, Alireza
    Shin, Samuel
    Cooper, Benjamin
    Srivastava, Archita
    Bhandari, Mohit
    Kondziolka, Douglas
    JOURNAL OF NEURO-ONCOLOGY, 2015, 124 (03) : 345 - 356
  • [35] Randomized controlled trials and neuro-oncology: should alternative designs be considered?
    Alireza Mansouri
    Samuel Shin
    Benjamin Cooper
    Archita Srivastava
    Mohit Bhandari
    Douglas Kondziolka
    Journal of Neuro-Oncology, 2015, 124 : 345 - 356
  • [36] Randomised controlled trials for multisystemic therapy: when is enough, enough? Reply
    Fonagy, Peter
    LANCET PSYCHIATRY, 2018, 5 (05): : 390 - 390
  • [37] Response to 'Randomised controlled trials do not always give the results we want but that doesn't mean we should abandon randomised controlled trials'
    Wernig, A.
    SPINAL CORD, 2015, 53 (12) : 897 - 898
  • [38] Response to ‘Randomised controlled trials do not always give the results we want but that doesn’t mean we should abandon randomised controlled trials’
    A Wernig
    Spinal Cord, 2015, 53 : 897 - 898
  • [39] When should case-only designs be used for safety monitoring of medical products?
    Maclure, Malcolm
    Fireman, Bruce
    Nelson, Jennifer C.
    Hua, Wei
    Shoaibi, Azadeh
    Paredes, Antonio
    Madigan, David
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 50 - 61
  • [40] Should randomised controlled trials be the "gold standard'' for research on preventive interventions for children?
    Stewart-Brown, Sarah
    Anthony, Rebecca
    Wilson, Lynsey
    Winstanley, Sarah
    Stallard, Nigel
    Snooks, Helen
    Simkiss, Douglas
    JOURNAL OF CHILDRENS SERVICES, 2011, 6 (04) : 228 - 235